Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
Apollomics (Nasdaq: APLM) said Nasdaq notified the company on October 14, 2025 that the Listing Qualifications Staff determined Apollomics is in compliance with Nasdaq continued listing requirements.
As a result, Nasdaq cancelled the previously scheduled appeal hearing and Apollomics securities will remain listed and continue to trade on The Nasdaq Stock Market. The company had earlier filed an application to appeal a delisting notification and requested a hearing before a Nasdaq Hearings Panel.
Apollomics (Nasdaq: APLM) ha comunicato che Nasdaq ha notificato all'azienda il 14 ottobre 2025 che lo Staff delle Listing Qualifications ha determinato che Apollomics è in conformità con i requisiti di listing continuo di Nasdaq.
Di conseguenza, Nasdaq ha cancellato l'udienza di appello precedentemente fissata e i titoli di Apollomics rimarranno quotati e continueranno a essere negoziati sul Nasdaq Stock Market. In precedenza l'azienda aveva presentato una domanda di ricorso contro una notifica di delisting e aveva richiesto un'udienza davanti a un Nasdaq Hearings Panel.
Apollomics (Nasdaq: APLM) dijo que Nasdaq notificó a la empresa el 14 de octubre de 2025 que el personal de Listing Qualifications determinó que Apollomics cumple con los requisitos de listado continuo de Nasdaq.
Como resultado, Nasdaq canceló la audiencia de apelación previamente programada y las acciones de Apollomics seguirán cotizando y operando en The Nasdaq Stock Market. La compañía había presentado previamente una solicitud para apelar una notificación de eliminación y solicitó una audiencia ante un Nasdaq Hearings Panel.
Apollomics (Nasdaq: APLM)가 Nasdaq가 2025년 10월 14일 회사에 통지했으며 Listing Qualifications 직원이 Apollomics가 Nasdaq의 지속 상장 요건을 충족한다고 결정했다는 사실을 공지했다고 밝혔다.
그 결과 Nasdaq는 이전에 예정되어 있던 항소 심리를 취소했고 Apollomics의 증권은 Nasdaq Stock Market에서 계속 상장되어 거래될 것입니다. 회사는 이전에 상장폐지 통지에 대한 항소를 제기했고 Nasdaq 심리위원회 앞에서 심리를 요청했습니다.
Apollomics (Nasdaq: APLM) a déclaré que Nasdaq a informé l'entreprise le 14 octobre 2025 que le personnel des Listing Qualifications avait déterminé qu'Apollomics était en conformité avec les exigences de cotation continues de Nasdaq.
En conséquence, Nasdaq a annulé l'audience d'appel précédemment prévue et les titres d'Apollomics resteront cotés et continueront à être négociés sur The Nasdaq Stock Market. La société avait auparavant déposé une demande d'appel d'une notification de radiation et avait demandé une audience devant un Nasdaq Hearings Panel.
Apollomics (Nasdaq: APLM) sagte, dass Nasdaq dem Unternehmen am 14. Oktober 2025 mitgeteilt habe, dass das Listing Qualifications Staff festgestellt habe, dass Apollomics die fortlaufenden Listing-Anforderungen von Nasdaq erfüllt.
Infolgedessen habe Nasdaq die zuvor geplante Berufungssitzung storniert und Apollomics-Wertpapiere werden gelistet bleiben und weiter am Nasdaq Stock Market gehandelt. Das Unternehmen hatte zuvor einen Antrag auf Berufung gegen eine Delisting-Benachrichtigung gestellt und eine Anhörung vor einem Nasdaq Hearings Panel beantragt.
Apollomics (Nasdaq: APLM) قالت إن Nasdaq أبلغت الشركة في 14 أكتوبر 2025 بأن فريق متطلبات الإدراج قد قرر أن Apollomics تلبي متطلبات الإدراج المستمر في Nasdaq.
وبناء عليه، ألغت Nasdaq جلسة الاستئناف المقررة سابقاً وأن أسهم Apollomics ستبقى مدرجة وتُتداول في Nasdaq Stock Market. كانت الشركة قد قدمت سابقاً طلباً لاستئناف إشعار الإلغاء وطلبت جلسة أمام لجنة الاستماع بنطاق Nasdaq.
Apollomics (Nasdaq: APLM) 表示，纳斯达克在 2025年10月14日 通知公司，上市资格部认定 Apollomics 符合纳斯达克持续上市要求。
因此，纳斯达克取消了之前安排的上诉听证会，Apollomics 的证券将继续在纳斯达克交易所上市并交易。公司此前曾提交对退市通知的上诉申请，并请求在纳斯达克听证委员会前进行听证。
- Nasdaq compliance determination issued on Oct 14, 2025
- Company remains listed and shares continue trading on Nasdaq
- Company previously received a delisting notification and filed an appeal
- Listing uncertainty persisted until Nasdaq’s Oct 14, 2025 decision
Nasdaq Hearing Cancellation and Continued Listing
FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, had previously announced that it had filed an application to appeal the delisting notification previously received from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) and request a hearing before a Nasdaq Hearings Panel to review the Staff’s delisting determination. The Company today announced that it had received a letter from Nasdaq on October 14, 2025, notifying Apollomics the Staff had determined that the Company is in compliance with Nasdaq’s continued listing requirements. Accordingly, Nasdaq has cancelled its appeal hearing and the Company’s securities will remain listed and continue to trade on The Nasdaq Stock Market.
About Apollomics Inc.
Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and other countries. For more information, please visit www.apollomicsinc.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding Apollomics’ strategy, prospects, plans, objectives and anticipated outcomes from the development and commercialization of vebreltinib, future proceedings with respect to the Cayman Litigation, or the appeal of, response to, or outcome of the Nasdaq delisting notification, are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “seek,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2024, filed by Apollomics Inc. with the U.S. Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and the other documents filed, or to be filed, by Apollomics with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will file from time to time with the SEC. Forward-looking statements speak only as of the date made by Apollomics. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law.
Investor Contacts: Apollomics: Peter Lin, Chief Financial Officer Apollomics, Inc. Phone: 1-650-209-4055 Email: peter.lin@apollomicsinc.com
FAQ
What did Apollomics announce about its Nasdaq listing on October 15, 2025?
Will Apollomics (APLM) shares remain listed on Nasdaq after the hearing cancellation?
Why was a Nasdaq hearing initially requested by Apollomics (APLM)?
On what date did Nasdaq notify Apollomics of continued compliance for APLM?
Does the Nasdaq decision on Oct 14, 2025 affect Apollomics trading status immediately?
What should investors in APLM expect after Nasdaq cancelled the hearing?
